{"id":"mrna-1273-variant-containing-formulation","brandName":"mRNA-1273 Variant-containing Formulation","genericName":"mRNA-1273 Variant-containing Formulation","companyId":"modernatx-inc","companyName":"ModernaTX, Inc.","phase":"marketed","status":"active","modality":"Biologic","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"mRNA-1273 is ModernaTX's marketed mRNA vaccine targeting COVID-19 prevention in adults 18+. The vaccine leverages Moderna's proprietary mRNA platform to encode the SARS-CoV-2 spike protein, enabling rapid immune response generation. This variant-containing formulation represents an evolution of the original vaccine, designed to address emerging viral variants and maintain clinical efficacy. With 4 clinical trials supporting its development and significant commercial deployment, mRNA-1273 demonstrates the viability of mRNA technology for infectious disease prevention. The vaccine's success has established mRNA as a validated modality and positioned Moderna as a leader in next-generation vaccine development.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is an updated mRNA vaccine formulation that contains genetic instructions for producing spike proteins from circulating SARS-CoV-2 variants (such as Omicron subvariants). When administered, the mRNA is taken up by cells, translated into variant spike proteins, and presented to the immune system to generate antibodies and T-cell responses against those specific variants. This approach aims to provide improved protection against evolving viral strains.","oneSentence":"mRNA-1273 Variant-containing Formulation encodes instructions for cells to produce spike proteins from SARS-CoV-2 variants, triggering an immune response against those variants.","_ai_confidence":"high"},"administration":{},"safety":{"commonSideEffects":[{"rate":"50-70","effect":"Injection site pain"},{"rate":"30-50","effect":"Fatigue"},{"rate":"30-50","effect":"Headache"},{"rate":"20-40","effect":"Myalgia"},{"rate":"10-20","effect":"Fever"},{"rate":"10-20","effect":"Chills"}]},"trials":[],"indications":{"approved":[{"name":"COVID-19 prevention (variant-containing booster formulation)"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT06585241","phase":"PHASE4","title":"A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2024-09-09","conditions":["SARS-CoV-2"],"enrollment":1144,"completionDate":"2026-12-31"},{"nctId":"NCT07279766","phase":"PHASE4","title":"Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2025-12-11","conditions":["COVID-19"],"enrollment":285000,"completionDate":"2026-08"},{"nctId":"NCT07266558","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2025-11-26","conditions":["SARS-CoV-2"],"enrollment":30000,"completionDate":"2027-06-16"},{"nctId":"NCT05289037","phase":"PHASE2","title":"COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-03-30","conditions":["COVID-19"],"enrollment":1270,"completionDate":"2023-11-27"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}